Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
Evaxion is expanding its pipeline with EVX-05, an off-the-shelf therapeutic vaccine for glioblastoma developed using its AI-Immunology™ platform. The company is collaborating with Duke University School of Medicine to conduct initial clinical testing, while discontinuing the EVX-03 program as part of portfolio management.
Key figures
- Cash runway
- second half of 2027
- Patient mortality median
- 1 year
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.